



University of Szeged 
Faculty of Pharmacy 



















Dr. habil. Géza Regdon jr., PhD 
and 




University of Szeged 
 
 
Graduate School of Pharmaceutical Sciences 
 
 
Educational program: Pharmaceutical Technology 
Head: Prof. Dr. habil. Ildikó Csóka, PhD. 
 
Institute of Pharmaceutical Technology and Regulatory Affairs 






The utilization of titanate nanotubes as drug delivery systems 
 
 
Final Exam Committee: 
Head: Prof. Dr. Piroska Révész, D.Sc., University of Szeged, Institute of 
Pharmaceutical Technology and Regulatory Affairs 
Members: Dr. Ildikó Bácskay, Department of Pharmaceutical Technology, University of 
Debrecen.  
Dr. habil. Aigner Zoltán, University of Szeged, Institute of Pharmaceutical 
Technology and Regulatory Affairs 
 
Reviewer Committee: 
Head: Prof. Dr. Loránd Kiss, DSc, University of Szeged Faculty of Pharmacy, 
Institute of Pharmaceutical Chemistry 
Reviewers: Prof. Dr. Romána Zelkó, DSc, Semmelweis University, University Pharmacy, 
Institute of Pharmaceutical Organization 
Prof. Dr. Miklós Vecsernyés, DSc, University of Debrecen Faculty of 
Pharmacy, Department of Pharmaceutical Technology 
Members: Dr. Attila Hunyadi, PhD, University of Szeged Faculty of Pharmacy, 
Department of Pharmacognosy 
Dr. Péter Doró, PhD, University of Szeged Faculty of Pharmacy, Department 









Conventional drug delivery systems may have limitations such as poor solubility, fluctuation 
in plasma concentration, patient incompliance, concentration decrease at the site of action, and 
poor pharmacokinetics (PK). In contrast, nanotechnology-based drug delivery systems can help 
in delivering sparingly water-soluble drugs to their target location, achieving higher oral 
bioavailability and prolonging the drug blood circulation period. Furthermore, nanosized drugs 
may show better stability and, therefore, enhance the shelf life and acceptability of drugs by 
increasing either their uptake efficacy or patient compliance (1). 
Metallic, organic, inorganic and polymeric nanostructures are often used as targeted drug 
delivery systems, particularly for poorly soluble and poorly permeable APIs. The biophysical 
and chemical characteristics such as shape and size have a significant influence on 
nanostructure efficacy (2). Nanotubes have a surface area five times higher than that of other 
NPs and an ideal inner diameter of 5–6 nm, which is suitable for loading even with large 
biological molecules. Furthermore, tubular NPs can be cell internalized in a higher percentage 
compared to their spherical counterparts (3). 
The first nanotubes to be synthesized were carbon nanotubes (CNTs) in 1991 by Lijima, 
whereas titanate nanotubes (TNTs) were synthesized in 1996 by Hoyer. CNTs and TNTs 
display considerable similarities regarding their impressive mechanical, electrical, and optical 
properties. CNTs have promising results in drug delivery, but due to their high hydrophobicity, 
they accumulate in the human body, which leads to a risk of toxicity and carcinogenicity. Thus, 
CNTs are insoluble in aqueous solutions and cannot be used immediately in biomedical 
applications, whereas TNTs display strong hydrophilicity due to the capillary forces and their 
partially hydroxylated surface that can combine with hydrogen bonds causing outstanding 
wettability. Moreover, TNTs display excellent biocompatibility due to their good wettability 
and therefore improve cell adhesion. Based on the previously mentioned distinctive and 





Tablets are the most common solid dosage form amongst marketed medicines, and they 
enhance patient compliance thanks to their wide-ranging advantages. However, it has been 
detected that 60–70% of the drug molecules are poorly water-soluble and/or poorly permeable, 
which leads to difficulties in their absorption from the GIT following oral administration. Many 
approaches were taken to overcome this challenge, such as crystalline solid formulations 
including salt formation and micronization of the crystalline compound, amorphous 
formulations including solid solutions and other formulation strategies, and lipid formation 
including solid dispersion. Nevertheless, these methods still face many obstacles, such as the 
unachievable salt formation of neutral compounds, the undesired particle size reduction of 
poorly wettable drugs, the uncertain physical stability of the product, potential drug or polymer 
crystallization, or low surfactant tolerance in chronic use (5). Therefore, poorly water-soluble 
and poorly permeable drugs still pose a major challenge to be manufactured as tablets.  
TNTs have captivating characteristics, such as biocompatibility, hydrophilicity, surface 
chemistry, tunable geometries, and the ability to modify drug release kinetics. Furthermore, 
TNTs can load a higher amount of drug compared to CNTs and TNTs are superior to CNTs 
from the aspect of processability, biocompatibility and wettability (6).  
For this purpose, our study was performed to demonstrate the importance of not only the 
optimized TNT-drug composites as an oral drug delivery system, but also their 
functionalization effect on enhancing the drug absorption from the GIT. 
 
The main hypotheses of my research work were as follows: 
I. The optimization of the product quality of TNT-drug composites may be achieved by 
choosing a solvent with proper characteristics, e.g., dissolving ability, protic-aprotic 
nature and evaporation properties 
II. The functionalization of TNTs enables their hydrophobicity, to be tailored, thereby 
improving their permeability. 





3.1. Hydrothermally synthetized titanate nanotubes and their composites 
TiO2 and NaOH were used to prepare the hydrothermal TNTs. HCl 0.01 M was used to 
prepare TiHCl. Atenolol (ATN) (TEVA Pharmaceuticals PLC, Debrecen, Hungary), methanol 
(0.0168% water content) (Molar Chemicals Kft, Hungary) and 0.01 M aqueous solution of HCl 
(HCl 0.01 M) (Molar Chemicals Kft, Hungary) were applied to prepare TNT-ATN composites 
(TiATN). Hydrochlorothiazide (HCT) (TEVA Pharmaceuticals PLC, Debrecen, Hungary), 1 
M aqueous solution of sodium hydroxide (NaOH 1M) (Molar Chemicals Kft, Hungary), DMF 
(0.012% water content) (Molar Chemicals Kft, Hungary), and DMSO (0.027% water content) 
(Molar Chemicals Kft, Hungary) were used for the synthesis of TNT-HCT (TiHCT).  
3.2.  Functionalization 
Trichloro-octyl-silane (TCOS) (Sigma-Aldrich, St. Louis, Missouri, United States) and 
stearate (St) (VWR International, Radnor, PA, United States) were used to functionalize TNTs. 
4. METHODS 
4.1.  Preparation of TNTs and their composites 
4.1.1. Hydrothermal synthesis of TNTs 
4.1.1.1. Pristine sodium trititanate (Na2Ti3O7) nanotubes (TNTs) 
NaOH was added to distilled water on a magnetic stirrer and then TiO2 was added. The 
mixture was put in the autoclave inside a dry oven at 185 °C for 24 h and then cooled. After 
that, TNTs were washed with distilled water under vacuum and by using filter No#4. 
4.1.1.2. Hydrogen trititanate (H2Ti3O7) nanotubes (H-TNTs) 
TNTs were added to HCl 0.01 M in an ultrasonic bath. After that, HCl 0.01 M was added to 
the previous suspension on a magnetic stirrer and the mixture was dried in a dry oven for 24 h 
to remove the solvent. 
4.1.1.3. Magnesium trititanate (MgTi3O7) nanotubes (Mg-TNTs) 
Na-TNT was added to 0.1M MgCl2 solution on a magnetic stirrer for 1 day. Then, the 
mixture was filtered by using glass filter No#4 under vacuum to obtain Mg-TNTs. This 
procedure was repeated three times to make sure that no Na-TNTs existed anymore. Finally, 





4.1.2. Preparation of TNT-drug composites 
4.1.2.1. TiATN-Methanol/ TiATN-HCl/ TiHCT-DMF/ TiHCT-DMSO/ TiHCT-NaOH 
1:1 ratio of these composites were prepared by adding TNTs in the respective solvent in an 
ultrasonic bath, and ATN or HCT in the solvent on a magnetic stirrer. Then, the two prepared 
mixtures were added to each other on a magnetic stirrer until a homogenous mixture was 
obtained which was put in a vacuum distillation device to remove the solvent. However, HCl 
37% was added to the final mixture of TiHCT-NaOH for neutralization and then was washed 
with distilled water in a vacuum dryer until pH = 9 to eliminate the solvent and was dried in a 
drying oven (Sanyo Electric Co., Ltd, Osaka, Japan).  
4.2.  Functionalization of TNTs 
4.2.1.  TCOS-TNTs  
H-TNTs were added to toluene in ultrasonic bath for 1 h. After that, the suspension was 
heated to 80 °C in a condenser connected to nitrogen gas for 30 min. Then, TCOS reagent was 
added to the previous system in different concentrations, e.g. 1- 2- 10- 50- 100- 500- 1000 µl, 
covering the 0.001:1 - 2:1 molar ratios, respectively and mixed for one day. Finally, the 
functionalized TNTs were washed by hexane 8 times and dried in a drying oven at 80 °C. 
4.2.2.  MgSt- TNTs 
Mg-TNTs was added to distilled water in ultrasonic bath for 30 min. Following that, the 
mixture was heated to 80 °C in a magnetic stirrer and Na stearate VWR International was added 
in different (e.g. 0.001:1-0.1:1) molar ratios for 1 night. Finally, St-TNTs were filtered by using 
filter No#4 under vacuum and dried in a drying oven.  
4.3.  Morphology and size investigation 
Scanning electron microscope (SEM) (Hitachi 4700, Hitachi Ltd., Tokyo, Japan) and 
transmission electron microscope (TEM) (FEI Tecnai G2 20 X-TWIN, Hillsboro, OR, USA) 
were used to study the morphology and size of TNTs.  
4.4.  FT-IR spectrophotometer  
The interactions between the APIs and the TNTs were determined by using a Thermo Nicolet 




4.5. Surface free energy measurement 
The surface free energy was determined with a DataPhysics OCA20 (DataPhysics 
Instruments GmbH, Filderstadt, Germany) optical contact angle tester by using the sessile drop 
method.  
4.6. Thermoanalytical analysis 
A TGA/DSC1 simultaneous analyzer (Mettler-Toledo Ltd., Budapest, Hungary) was used to 
investigate the thermal behavior of TNTs, APIs, and composites. STARe Software (Mettler-
Toledo Ltd, Budapest Hungary) was used to assess the curves. 
4.7. Drug release  
A DT700 (Erweka GmbH, Heusenstamm, Germany) dissolution tester was used to study drug 
release using the USP II method. A GENESYS 10S UV–VIS spectrophotometer (Thermo 
Fisher Scientific Ltd., Waltham, MA, USA) was used to measure the concentrations of the 
released drug which were assessed with Sigmaplot v12 (Systat Sofware Inc., San Jose, CA, 
USA) software. 
4.8. CHNS elemental analysis 
The content of carbon, hydrogen, nitrogen, and sulphur in organic materials was investigated 
rapidly by conducting CHNS elemental analysis. A Vario EL cube elemental analyzer 
(Elementar, Langenselbold, Germany) was used to analyze H, C, N, and S contents in the 
samples. 
4.9. Cytotoxicity and permeability detection 
Permeability and cytotoxicity experiments were tested on a Caco-2 human adenocarcinoma 
cell line in which energy dispersive X-ray fluorescent analyzer (Philips MiniPal PW 4025, 
Philips Analytical, the Netherlands) and MTT assay were used to measure the permeability and 
cytotoxicity, respectively.  
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5. RESULTS AND DISSCUSSION 
5.1. Optimization of the composite formation process and product quality 
Based on the results of a previous study (7) the quality of TNT-drug composites is also 
related to the parameters of the chosen solvent. Thus, in our first hypothesis we have identified 
the protic-aprotic nature, the volatility, and the solubility of drugs as key factors of optimal 
solvent selection, in which we could achieve a strong interaction between the drug and the 
carrier.  
5.1.1. Properties of the TNT and TNT-HCl 
The first step of our study was to test the reproducibility and robustness of the previously 
described synthesis method of TNTs (7) to ensure constant quality since the synthesis 
conditions affect strongly affect the dimensions and surface characteristics of TNTs. 
The TEM images (Figure 1a) showed that the prepared TNTs have an average length of 
116.22 nm (SD ± 49.49 nm) and an average diameter of 10.99 nm (SD ± 10.15 nm), which 
considerably approaches the previously described results of Sipos et al.  
The SEM images (Figure 1b) displayed the characteristic aggregates of almost distinct and 
randomly oriented TNTs. Furthermore, there was no considerable difference in the surface 
characteristics of the new and the previous batch of TNTs according to the contact angle 
measurements (Table 1). 
 





Table 1: Surface free energy and polarity of TNTs, atenolol (ATN), hydrochlorothiazide 











TNTs (previous) 80.72 ±0.64 43.78 ±0.54 36.94 ±0.35 45.76 
TNTs (current) 80.85 ±1.18 44.55 ±0.53 36.31 ±1.04 44.90 
TNT-HCl  78.63 ±2.07 43.10 ±0.27 35.53 ±2.05 45.19 
ATN 59.48 ±3.99 36.70 ±2.96 22.77 ±2.68 38.20 
TiATN-ethanol 60.14 ±4.25 40.45 ±1.48 19.68 ±3.87 32.72 
TiATN-methanol 58.04 ±2.01 37.12 ±1.19 20.92 ±1.47 36.04 
TiATN-HCl 68.37 ±2.26 34.83 ±0.05 33.54 ±2.26 49.06 
HCT 69.51 ±2.71 43.33 ±0.79 26.18 ±2.59 37.60 
TiHCT-ethanol 78.25 ±0.86 44.65 ±0.57 33.60 ±0.64 42.93 
TiHCT-NaOH 1M 77.54 ±1.89 44.52 ±0.80 33.02 ±1.71 42.59 
TiHCT-DMF 71.47 ±2.63 42.53 ±0.29 28.94 ±2.63 40.49 
TiHCT-DMS 73.92 ±1.42 45.29 ±0.08 28.63 ±1.42 38.72 
The effect of diluted 0.01 M HCl on the properties of TNTs was tested by preparing TNT–
HCl samples as a reference (Figure 1c, d). The TEM images showed a slight decrease in the 
dimensions of TNT-HCl compared to native TNTs, with an average length of 83.92 nm (SD ± 
42.48 nm) and an average diameter of 8.78 nm (SD ± 1.76 nm). Nevertheless, neither the surface 
characteristics (Table 1) nor the FT-IR spectrum (Fig. 2) displayed a considerable difference 
from the results of native TNTs. Therefore, no noteworthy difference was expected in the 
behavior of TNT and TNT–HCl from the aspect of composite formation ability. 
 
Figure 2. FT-IR spectra of TNTs and TNT–HCl 0.01 M 
5.1.2. Effect of various solvents on composite formation with ATN 
In the previous study of (7) it was confirmed that composite formation was insufficient for 
TiATN-ethanol (Fig. 3b) since both the aggregates of TNTs and the smooth surfaced particles 
of crystalline ATN (Fig. 3a) were clearly visible in the SEM images. A stronger interaction but 
still insufficient composite formation was observed in the TiATN-methanol sample (Fig. 3c). 
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Interestingly, a rough surface and highly ordered aggregations were detected in TiATN-HCl 
which indicates a more adequate composite formation (Fig. 3d).  
The OCA measurement (Table 1) showed that the γs for TiATN-ethanol, TiATN-methanol 
and ATN were almost identical to each other, which may indicate not pure TNTs but TNT-
ATN composites aggregated to the surface of bigger ATN particles. In contrast, distinctly 
different values of γs and polarity for TiATN-HCl were detected, which may reflect not only a 
kind of interaction between NH3
+ from ATN and the hydrophilic sites in TNTs enriching the 
hydrophobic regions in TNTs, but also a different particle forming mechanism than in the case 
of other solvents, which leads to a different expected behavior during processing and use. 
 
Figure 3. SEM micrographs of atenolol (a), TiATN-ethanol (b), TiATN-methanol (c), and 
TiATN-HCl 0.01 M (d) 
Fig. 4a displays that the DSC curve of ATN contains an endothermic and a broad exothermic 
peak. The sharp endothermic peak at 155.21 °C represents the fusion of the compound and the 
exothermic peak describes its decomposition, which is supported by the TG curve of ATN. The 
enthalpy of fusion for this peak in TiATN-ethanol and TiATN-methanol was declined which 
may indicate the poor composite formation. On the other hand, a significant decrease in the 
fusion enthalpy to -40.55 Jg-1 were detected in the TiATN-HCl composite, which may be 
resulted due to the stronger interactions and the considerable particle size reduction of ATN.  
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Figure 4. DSC and TG curves of TNT, ATN, TiATN-methanol, TiATN-ethanol and TiATN-
HCl (a) and TNT, HCT, TiHCT-ethanol, TiHCT-NaOH, TiHCT-DMF and TiHCT-DMSO (b) 
These results were supported by the FT-IR spectra, which displayed no substantial 
differences between the spectra of ATN, TiATN-ethanol and TiATN-methanol (Fig. 5). On the 
other hand, changes in the TiATN-HCl spectrum were observed, namely the appearance of a 
new peak at 1560 cm-1, indicating the protonation of the carbonamide group and wide low 
intensity peaks between 1900-2100 cm-1 and 2300-2500 cm-1, indicating the protonation of the 
secondary amino group.  
 
Figure 5. FT-IR spectra of ATN and its composites (a) and HCT and its composites (b) 
However, the strongest reaction between TNTs and ATN was achieved by using HCl 0.01 
M as a solvent in spite of the slow evaporation rate, which can be explained by the protonation 
of the carboxyl amide and secondary amino groups of ATN, resulting in repulsion between 
ATN molecules and in a possible increase in their H-bonding strength in the presence of 
polyfunctional carriers as TNTs. These effects also cause characteristic ATN-TNT interactions, 
which result in an increased dissolution rate from the composites due the formation of stable 
nanocrystals on the surface of the carrier (Fig. 6a). 
In conclusion, ATN shows good solubility in 70 w/w% ethanol solution, methanol and HCl 
0.01M. The Janus-faced properties of the TiATN-ethanol sample can be explained by the fast 




followed by the slower speed of water removal, which induced the concentration of ATN 
molecules and promoted the formation of ATN-ATN bonds instead of ATN-TNT ones. This 
latter effect was not observed during the fast removal of water-free methanol, whereas the 
repulsive effect between protonated ATN molecules prohibited the formation of ATN-ATN 
interactions despite the slower solvent removal speed in 0.01 M HCl solution. 
 
Figure 6. Dissolution study of TiATN (a) and TiHCT (b) composites in gastric juice (non-
sink conditions) 
5.1.3. Effect of various solvents on composite formation with HCT 
The SEM micrographs display the strong recrystallization of HCT (Fig. 7a) from ethanol 
and NaOH (Fig. 7b,c) with the appearance of HCT crystals covered by the composites. On the 
other hand, no considerable recrystallization was observed in TiHCT-DMF and TiHCT-DMSO 
(Fig. 7d,e), and only strong compacts of TNTs with increased thickness are visible, which 
suggests an appropriate loading of the nanotubes with the API, which was also supported by 
the results of the OCA measurements (Table 1) and DSC analysis.  
The OCA results showed that γs and polarity values for TiHCT-ethanol and TiHCT-NaOH 
were higher compared to HCT due to the accumulation of TNTs on the surface of HCT crystals. 
In contrast, TiHCT-DMF and TiHCT-DMSO revealed γs values similar to HCT due to the 
surface coverage of TNTs with HCT molecules. 
The DSC curve (Fig. 4b) of HCT shows that the fusion of the API could be recognized near 
270.67 °C, which was followed by a characteristic exothermic event near 320 °C, ascribed to 
the decomposition of the material. The TiHCT-NaOH composite exhibited a slight shift in the 






Figure 7. SEM micrographs of HCT (a), TiHCT-ethanol (b), TiHCT-NaOH (c), TiHCT-
DMF (d), TiHCT-DMSO (e) 
TiHCT-ethanol and TiHCT-DMF revealed a higher shift in the melting peak which indicates 
a stronger interaction. Nevertheless, an improved composite formation was observed in DMF, 
but interestingly, no fusion peak can be seen in the case of TiHCT-DMSO composites, which 
can be explained by the formation of amorphous HCT particles instead of nanocrystals. All 
those findings were in accordance with the results of the XRPD results (Fig. 8). 
The X-ray diffractogram of TiHCT-DMSO shows only the characteristic peaks of the 
crystalline TNTs, which clearly shows HCT bonding with TNTs in an amorphous form, which 
is highly expected to ensure an improved dissolution rate, whereas the other composites 
contained HCT in a (nano)crystalline form. However, a new polymorphic form of HCT was 
recrystallized from DMF (the metastable Form II or DMF solvate instead of the starting stable 
Form I) (8). 
The FT-IR spectra were normalized to the peak at 1319 cm-1 (Fig. 5b). The peaks at 3391 
cm-1 shows non-associated NH stretching, and the right shift of this peak at 3269 cm-1 indicates 
the increasing strength of interactions in TiHCT composites in ethanol, NaOH, DMF, DMSO, 
respectively. The merging of these peaks in DMSO suggests a very strong association, which 




Figure 8. XRPD spectra of HCT and its composites 
The strength of interactions fundamentally determines the dissolution rate of the drug from 
the composites (Fig. 6b). There was no considerable difference in the dissolution rates of pure 
HCT and TiHCT-ethanol composite, in which the weakest interaction was observed. The 
increasing strength of the interactions resulted in a controlled dissolution rate and led to the 
switch of release kinetics from first order to power law model described by Korsmeyer and 
Peppas. TiHCT-DMSO exhibited the most considerable elongation of drug release. It is well 
visible that the decrease in the release rate of TiHCT-NaOH was higher than expected, which 
may be due to the large size of the HCT particles due to the slow recrystallization of the drug 
from the solvent. 
In conclusion, HCT was dissolved in 70 w/w% ethanol solution and NaOH 1 M as an analog 
of the experiments with ATN. DMF and DMSO were successful in forming the TiHCT 
composites since H-bonding was featured between HCT and TNTs due to the lack of drug-
solvent interactions. Nevertheless, despite the stabilized nanocrystalline form or HCT 
“recrystallizing” from DMSO in an amorphous form, an extended release of HCT from the 
composites was noted due to the very strong drug-carrier interactions. 
Overall, the assumptions of the first hypothesis were confirmed as protic-aprotic nature, 
solvent volatility and drug solubility play key roles in the composite formation process. The 
formation of strong TNT-API composites may be achieved optimally by choosing a highly 
volatile aprotic solvent. Nevertheless, the use of protic solvents should be considered if the drug 
is protonable. However, the high strength of drug-carrier interactions may influence drug 
detachment, and thus the final product characteristics, including release rate and behaviour in 
biological environment. The strength of interactions may be optimized by tailoring the surface 
characteristics of TNTs by functional modifications. 
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5.2. The functionalization of TNTs 
In the present part of the study, TCOS and MgSt were selected to functionalize the TNTs, to 
prove that the functionalization of hydrophilic TNTs with hydrophobic materials is a good 
technique to enhance their absorption into the systemic circulation.  
5.2.1. Physical properties of the functionalized TNTs 
Pristine Na-TNTs (Fig 9a) have a considerably elongated structure with an external diameter 
of 8-12 nm, and highly variable length (100-1000 nm). H-TNTs (Fig 9b) show identical 
physical dimensions but have an increased aggregation tendency due to the decreasing 
electrostatic repulsion resuling from the removal of Na+ ions. Mg-TNTs (Fig. 9c) have the same 
diameter of 8-12 nm but the mechanical agitation during the ion-exchange procedure resulted 
in considerable fragmentation, so the length of the nanotubes varies mostly in the 100-300 nm 
range. Similar fragmentation of the longer nanotubes was observed in the case of the 
functionalized samples (Fig. 9d-g) along with a slight increment of the diameter, which depends 
on the amount and orientation of the functionalizing agent on the surface of TNTs. 
Nevertheless, all samples have a strongly elongated tubular structure with an aspect ratio >10. 
The OCA measurement showed a gradual increment in optical contact angle with the 
increasing concentration of TCOS and complete surface coverage was achieved by the 
application of 100 µL reagent volume (e.g. 0.2:1 molar ratio). These results were supported by 
the CHNS elemental analysis, which displayed a continuous augmentation in carbon percentage 
with the increasing amount of functionalizing TCOS (Fig.10).  
 
 
Figure 9. SEM of Na-TNT (a), H-TNT (b), Mg-TNT (c), TCOS-TNT 10 (d), TCOS-TNT 50 




Figure 10. The aqueous contact angles (CA) and carbon percentage (C%) of TCOS-TNTs 
and St-TNTs at different reagent concentrations (CA of TCOS-TNT (black line); C% of 
TCOS-TNT (black dashed line), CA of St-TNT (red line), C% of St-TNT (red dashed line) 
In contrast, the OCA measurement revealed that low concentrations of St could just slightly 
increase OCA of Mg-TNTs, but after exceeding of a certain threshold around 0.035:1 ratio and 
despite the linear increment of the carbon content, the surface turned from hydrophilic to 
hydrophobic (Fig. 10). A possible explanation that above this threshold the St molecules are 
oriented differently on the surface of TNTs, prohibiting the access of water to the sample. After 
that only a slight increment could be detected until it stabilizes between 80-90°, but it should 
be noted, that the maximum aqueous contact angle is considerably smaller as in the case of 
TOCS-TNTs. Less St coverage resulted in getting a hydrophobic surface that may bear an 
advantage of keeping more binding sites for the drugs which may lead to a higher possible drug 
load in this system. 
5.2.2. Toxicity and permeability of functionalized TNTs 
In a previous study (9), no detectable cytotoxicity of Na-TNTs was observed up to a 
concentration of 5 mg/mL, but in the current study a considerable decrease in cell viability was 




Figure 11. The viability assays of Caco-2 cells after being exposed to functionalized TNTs 
This may indicate that the replacement of Na+ to Mg2+ ions on the surface of TNTs also has 
negative influence on cell interactions, but based on the MTT cytotoxicity test, it is still 
considered as non-cytotoxic in the concentration range of 0,01-2 mg/mL. In addition, 
considerable differences were observed in the toxicity of various functionalized TNTs, 
especially at higher concentrations. 
The toxicity results displayed a considerable decrease in cell viability in for TCOS-TNT 10- 
and 50- µL samples, possibly due the use of H-TNT as a starting material. On the other hand, 
the lower toxicity presented by MgSt-TNTs which was similar to Mg-TNTs, indicates that the 
effect may be connected to the presence of Mg2+ ions and not to St molecules. 
5.2.3. Permeability results 
During the permeability test the highest safe concentration (1 mg/mL) was applied to achieve 
a higher maximum drug-dose during further utilization. The transepithelial electrical resistance 
(TEER) of the cells before TNT exposure was 602±116 Ω/cm2. For Caco-2 cells, this value 
may vary in a very large range (200-2400 Ω/cm2) (10), the obtained results indicate an intact 
cell layer. Nevertheless, a considerable decrease (22.1±16.7%, 12.4±11.1%, 37.1±8.4% and 
23.6±17.4% for TCOS-TNT 10, TCOS-TNT 50, St-TNT (0.05:1), and St-TNT (0.1:1) samples, 
respectively in the TEER values was observed after exposure to TNTs, which indicates the 
perturbation of the integrity of the cell membrane or tight-junctions. However, microscopic 
investigation showed no change in the cell morphology or layer-integrity, before and after the 
test, which may indicate a periodic distortion of the membrane integrity by the penetrating 
nanotubes. Nevertheless, the relative change of various samples showed partial correlation with 
the results of the permeability tests (Table 2), which revealed that the aqueous contact angle 
(CA) values should be between 60-90° to achieve appropriate absorption, while the cell 
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integrity was exhibited the smallest distortion for samples between 80-90°CA. Below 40° the 
surface is too hydrophilic to achieve passive transportation through the cell membrane, while 
in the 40-60° range the samples may be absorbed considerably slower than the ones with 60-
90° CA, and causes higher distortions in cell integrity, possibly due to the higher hydrophilicity. 
In a previous study (9) no detectable number of pristine Na-TNTs have been found on the 
basolateral side of the cell monolayer, indicating that the intestinal cell layer is impermeable to 
this material, possibly due to its high hydrophilicity. In contrast, present study revealed that 
functionalized samples exhibited considerable permeability through the cell monolayer (Table 
2). According to the results, the penetration of samples with small (30°) CA is hindered as more 
than 40% of the originally inserted value was still detected on the apical side. The best 
permeability rate was observed for samples with 70-90° CA, where the amount permeated to 
the basolateral side was increased with the increasing CA. In case of sample TCOS-TNT 100 
where the CA was around 140° no detectable amount was measured both in apical and basal 
compartment. A possible explanation that due to the inappropriate wetting and dispersion, the 
TNTs were sedimented and adhered to the cell layer without visible absorption through the 
membranes or were completely accumulated in the cells, which would bear a potential risk of 
toxicity. Nevertheless, in both cases the sample is inappropriate for the planned application.   
Table 2: Results of the permeability tests 
Material Aqueous CA (°) Apical amount (%) Basal amount (%) 
TCOS-TNT 10 27.70±2.10 40.94±10.49 8.47±0.30 
TCOS-TNT 50 86.66±1.90 27.94±14.83 8.39±0.24 
TCOS-TNT 100 146.65±0.60 n.m n.m 
St-TNT 47 71.75±3.58 26.98±  6.66 8.75±0.78 
St-TNT 94 89.55±7.66 27.16±11.13 11.49±0.67 
This part of the experimental work emphasized the importance of functionalizing the TNTs 
to improve their absorption after the oral administration. We have confirmed the second 
hypothesis, according to which increasing the hydrophobicity of TNTs may increase the cell 
permeability. Nevertheless, the validity of the third hypothesis, namely that the increased 
hydrophobicity may not affect the toxicity, should be partially reconsidered, since the 
functionalized samples exhibited slightly increased toxicity, but it was connected to the altered 
surface charge due to ion exchange during the functionalization procedure. 
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6. CONCLUSIONS AND PRACTICAL USEFULNESS  
In this study, TNT composites with ATN and HCT were prepared to improve the drug 
dissolution profile from the composites in which ATN and HCT were chosen as model drugs 
from the third and fourth classes of BCS.  
I. Choosing the appropriate solvent is essential from the aspect of composite formation 
efficacy. Solvent volatility is important, but its protic/aprotic nature depends on the drug 
properties, with protic solvents being preferable for protonable drugs, otherwise aprotic 
solvents are more advantageous. 
II. The extent of the strength of interaction between TNTs and drugs directly affects drug 
detachment inside the human body, thus it should be estimated based on the 
administered oral dosage form, in which weak interaction is enough in immediate 
release drugs and strong interaction is favored for extended-release purposes.  
TNTs were functionalized to obtain increased hydrophobicity and enhance their absorption 
from the GIT, with two different methods were compared to each other. For this purpose, TCOS 
and St were used in different concentrations with a view to optimizing the functionalization 
method and determining the optimal functionalization percentage.  
I. The functionalization of TNTs is crucial to enhance their hydrophobicity and therefore 
their permeability and may strengthen the interaction between TNTs and drugs.  
II. The toxicity of functionalized TNTs has to be checked due to the changed surface 
charge. 
 
The practical relevance and new approaches of this research work are the following 
I. Our hypothesis of choosing the optimal solvent proved to be a promising approach for 
enhancing the solubility of poorly water-soluble drugs. 
II. Functionalized TNTs are potential drug carriers for the oral administration route since 
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